Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: A structure-function relationship study

Chemical Research in Toxicology

Volumn 22, Issue 7, 2009, Pages 1325-1333

  Shimada, Tsutomu ^a   Tanaka, Katsuhiro ^a   Takenaka, Shigeo ^a   Foroozesh, Maryam K ^b   Murayama, Norie ^c   Yamazaki, Hiroshi ^c   Guengerich, F Peter ^d   Komori, Masayuki ^a  

^a Osaka Prefecture University   (Japan)

^b XAVIER UNIVERSITY OF LOUISIANA   (United States)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,3A,5A TETRAMETHOXYSTILBENE; 3A,4A DIMETHOXY 5,7 DIHYDROXYFLAVONE; 4A METHOXY 5,7 DIHYDROXYFLAVONE; 7,8 DIHYDROXYFLAVONE; ALPHA NAPHTHOFLAVONE; BENZOFLAVONE DERIVATIVE; BETA NAPHTHOFLAVONE; BIPHENYL DERIVATIVE; CYTOCHROME P450 1B1; ENZYME INHIBITOR; ESTRADIOL; ESTRONE; ETHER DERIVATIVE; ETHOXYRESORUFIN DEETHYLASE; ETHYL PROPARGYL ETHER; FLAVONOID; GALANGIN; ISOFLAVONE DERIVATIVE; METHYL PROPARGYL ETHER; NAPHTHALENE DERIVATIVE; PHENANTHRENE DERIVATIVE; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; IC 50; REVERSE TYPE 1 SPECTROSCOPY; SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

BIPHENYL COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; HYDROCARBONS, AROMATIC; KINETICS; NAPHTHALENES; PHENANTHRENES; PROTEIN BINDING; PYRENES; SPECTROPHOTOMETRY, ULTRAVIOLET; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67651002558     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900127s     Document Type: Article

References (43)

1. Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed. (Ortiz de Montellano, P. R., Ed.) pp 377-530, Kluwer Academic/Plenum Press, New York.
2. Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., and Sutter, T. R. (1996) Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 56, 2979-2984.
3. Shimada, T. (2006) Xenobiotic-metabolizing enzymes involved in activation and inactivation of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet. 21, 257-276.
4. Watanabe, J., Shimada, T., Gillam, E. M. J., Ikuta, T., Suemasu, K., Higashi, Y., Gotoh, O., and Kawajiri, K. (2000) Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10, 25-33.
5. Zheng, W., Xie, D. W., Jin, F., Cheng, J. R., Dai, Q., Wen, W. Q., Shu, X. O., and Gao, Y. T. (2000) Genetic polymorphism of cytochrome P450 1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9, 147-150.
6. Rylander-Rudqvist, T., Wedren, S., Granath, F., Humphreys, K., Ahlberg, S., Weiderpass, E., Oscarson, M., Ingelman-Sundberg, M., and Persson, I. (2003) Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24, 1533-1539.
7. Chun, Y.-J., Kim, S., Kim, D., Lee, S.-K., and Guengerich, F. P. (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61, 8164-8170.
8. Slaga, T. J., Jecker, L., Bracken, W. M., and Weeks, C. E. (1979) The effects of weak or non-carcinogenic polycyclic hydrocarbons on 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene skin tumorinitiation. Cancer Lett. 7, 51-59.
9. Marston, C. P., Pereira, C., Ferguson, J., Fischer, K., Hedstrom, O., Dashwood, W. M., and Baird, W. M. (2001) Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis. Carcinogenesis 22, 1077-1086.
10. DiGiovanni, J., Rymer, J., Slaga, T. J., and Boutwell, R. K. (1982) Anticarcinogenic and cocarcinogenic effects of benzo[e]pyrene and dibenz[a,c]anthracene on skin tumor initiation by polycyclic hydrocarbons. Carcinogenesis 3, 371-375.
11. Guengerich, F. P., Chun, Y.-J., Kim, D., Gillam, E. M. J., and Shimada, T. (2003) Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies. Mutat. Res. 523-524, 173-182.
12. Shimada, T., Upadhyaya, P., El-Bayoumy, K., Strickland, P. T., Sutter, T. R., Guengerich, F. P., and Yamazaki, H. (1997) Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. Cancer Res. 57, 4757-4764.
13. Doostdar, H., Burke, M. D., and Mayer, R. T. (2000) Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31-38.
14. Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E., Alworth, W. L., and Guengerich, F. P. (1998) Selectivity of polycyclic inhibitors for human cytochromes P450 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 11, 1048-1056.
15. Walle, T., Ta, N., Kawamori, T., Wen, X., Tsuji, P. A., and Walle, U. K. (2007) Cancer chemopreventive properties of orally bioavailable flavonoids - Methylated versus unmethylated flavones. Biochem. Pharmacol. 73, 1288-1296.
16. Shimada, T., and Guengerich, F. P. (2006) Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. Chem. Res. Toxicol. 19, 288-294.
17. Courter, L. A., Musafia-Jeknic, T., Fischer, K., Bildfell, R., Giovanini, J., Pereira, C., and Baird, W. M. (2007) Urban dust particulate matter alters PAH-induced carcinogenesis by inhibition of CYP1A1 and CYP1B1. Toxicol. Sci. 95, 63-73.
18. Mahadevan, B., Marston, C. P., Luch, A., Dashwood, W.-M., Brooks, E., Pereira, C., Doehmer, J., and Baird, W. M. (2007) Competitive inhibition of carcinogen-activating CYP1A1 and CYP1B1 enzymes by a standardized complex mixture of PAH extracted from coal tar. Int. J. Cancer 120, 1161-1168.
19. Shimada, T., Murayama, N., Okada, K., Funae, Y., Yamazaki, H., and Guengerich, F. P. (2007) Different mechanisms of inhibition for human cytochrome P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chem. Res. Toxicol. 20, 489-496.
20. Shimada, T., Murayama, N., Tanaka, K., Takenaka, S., Imai, Y., Hopkins, N. E., Foroozesh, M. K., Alworth, W. L., Yamazaki, H., Guengerich, F. P., and Komori, M. (2008) Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. Chem. Res. Toxicol. 21, 2313-2323.
21. Hopkins, N. E., Foroozesh, M. K., and Alworth, W. L. (1992) Suicide inhibitors of cytochrome P450 1A1 and P450 2B1. Biochem. Pharmacol. 44, 787-96.
22. McKendall, M. E., Smith, T. P., Anh, K., Ellis, J., McGee, T., Foroozesh, M., Zhu, N., and Klein Stevens, C. (2008) Methoxyflavone inhibitors of cytochrome P450. J. Chem. Crystallogr. 38, 231-237.
23. Kelley, A. T., Mesbah, J. Y., McKendall, M. E., Smith, T. P., and Foroozesh, M. (2004) Synthesis of a family of naphthyl propargyl ethers as potential cytochrome P450 inhibitors. J. Undergrad. Chem. Res. 3, 103-106.
24. Zhu, N., Lightsey, K., Foroozesh, M., Alworth, W., Chaudhary, A., Willett, K. L., and Klein Stevens, C. L. K. (2006) Naphthoflavone propargyl ether inhibitors of cytochrome P450. J. Chem. Crystallogr. 36, 289-296.
25. Bowman, B., Lightsey, D., McKendall, M., Smith, T., Zhu, N., Stevens, C. L. K., and Foroozesh, M. (2005) Synthesis of a family of biphenylpropagyl ethers as potential inhibitors of P450 enzymes. X-ray crystal structure of 2,2′-biphenyldipropargyl ether. J. Undergrad. Chem. Res. 2, 57-61.
26. Foroozesh, M., Primrose, G., Guo, Z., Bell, L. C., Guengerich, F. P., and Alworth, W. L. (1997) Propynylaryl acetylenes as mechanism-based inhibitors of cytochrome P450 1A1, 1A2, and 2B1 enzymes. Chem. Res. Toxicol. 10, 91-102.
27. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378.
28. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
29. Yoshida, Y., and Kumaoka, H. (1975) Studies on the substrate-induced spectral change of cytochrome P450 in liver microsomes. J. Biochem. (Tokyo) 78, 455-468.
30. Schenkman, J. B., Cinti, D. L., Orrenius, S., Moldeus, P., and Kraschnitz, R. (1972) The nature of the reverse type I (modified type II) spectral change in liver microsomes. Biochemistry 11, 4243-4251.
31. Jefcoate, C. R. (1978) Measurement of Substrate and Inhibitor Binding to Microsomal Cytochrome P- 450 by Optical-Difference Spectroscopy (Colowick, S. P., and Kaplan, N. O., Eds.) pp258-279, Academic Press, New York.
32. Kumaki, K., Sato, M., Kon, H., and Nebert, D. W. (1978) Correlation of type I, type II, and reverse type I difference spectra with absolute changes in spin state of hepatic microsomal cytochrome P-450 iron from five mammalian species. J. Biol. Chem. 253, 1048-1058.
33. Isin, E. M., and Guengerich, F. P. (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J. Biol. Chem. 281, 9127-9136.
34. Wen, X., and Walle, T. (2006) Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab. Dispos. 34, 1786-1792.
35. Walle, U. K., and Walle, T. (2007) Bioavailable flavonoids: Cytochrome P450-mediated metabolism of methoxyflavones. Drug Metab. Dispos. 35, 1985-1989.
36. Walle, T. (2007) Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin. Cancer Biol. 17, 354-362.
37. Moon, Y. J., Wang, X., and Morris, M. E. (2006) Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. in Vitro 20, 187-210.
38. Kim, H.-J., Lee, S. B., Park, S.-K., Kim, H. M., Park, Y. I., and Dong, M.-S. (2005) Effects of hydroxy group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes. Arch. Pharm. Res. 28, 1114-1121.
39. Sohl, C. D., Isin, E. M., Eoff, R. L., Marsch, G. A., Stec, D. F., and Guengerich, F. P. (2008) Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2: Highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding. J. Biol. Chem. 283, 7293-7308.
40. Lu, F., Zahid, M., Wang, C., Saeed, M., Cavalieri, E. L., and Rogan, E. G. (2008) Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev. Res. 1, 135-145.
41. Aziz, M. H., Kumar, R., and Ahmad, N. (2003) Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms. Int. J. Oncol. 23, 17-28.
42. Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler Ijaz, P. C. T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., and Burke, M. D. (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer 86, 774-778.
43. Geahlen, R. L., and McLaughlin, J. L. (1989) Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 165, 241-245.